<DOC>
	<DOCNO>NCT01064141</DOCNO>
	<brief_summary>The purpose study investigate potential co-administration first dose CYD Dengue vaccine childhood vaccination . Primary Objectives : - To describe safety CYD Dengue vaccine dose ; first dose give alone coadministered childhood vaccine . Secondary Objectives : - To describe immunogenicity CYD Dengue vaccine dose ; first dose give alone co-administered childhood vaccine .</brief_summary>
	<brief_title>A Study Dengue Vaccine Healthy Toddlers Aged 12 15 Months Philippines</brief_title>
	<detailed_description>Participants enrol 3-step enrollment randomize 1 4 treatment group . Groups 1 2 receive 5 vaccination , Groups 3 4 receive 6 vaccination ( childhood vaccine placebo co-administered first dose CYD Dengue vaccine 2 separate arm ) . All toddler receive pentavalent acellular pertussis combination vaccine Combo ( PENTAXIM® ) , plan approximately 10 month enrollment .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Toddler good health base medical history medical examination Toddler age 12 15 month day inclusion Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg Provision inform consent form sign parent ( ) legally acceptable representative ( independent witness require local regulation ) Participant parent/delegate able attend schedule visit comply trial procedure Completion previous vaccination program accord national immunization schedule , except measles Exclusion Criteria : Family member Investigator staff involve trial Chronic illness , opinion investigator , stage might interfere trial conduct completion Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History central nervous system disorder disease , include seizure History varicella , measles , mumps , rubella hepatitis A ; confirm either clinically , serologically , microbiologically Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion Previous vaccination measlesmumpsrubella , hepatitis A varicella Previous vaccination flavivirus diseases Known systemic hypersensitivity component vaccine , history lifethreatening reaction vaccine use trial vaccine contain substance Planned participation another clinical trial present trial period Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Receipt blood bloodderived product past 3 month , might interfere assessment immune response Planned receipt vaccine 4 week follow first trial vaccination Human immunodeficiency virus ( HIV ) seropositivity blood sample take screen Clinically significant laboratory abnormality , judge Investigator , blood sample take screen Temporary exclusion : vaccination postpone condition resolve : Febrile illness ( temperature ≥ 38°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment Receipt oral inject antibiotic therapy within 72 hour prior vaccination visit Any vaccination receive 4 week precede vaccination</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>CYD Dengue Vaccine</keyword>
	<keyword>Toddlers</keyword>
</DOC>